Glenmede Trust’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Glenmede Trust’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-44	Closed	–	–	2912
2016 Q1	$0	Hold	44	–	–	﹤0.01%	2870
2015 Q4	$0	Sell	44 -23	-34%	-$548	﹤0.01%	2951
2015 Q3	$1K	Hold	67	–	–	﹤0.01%	2679
2015 Q2	$3K	Sell	67 -2	-3%	-$120	﹤0.01%	2403
2015 Q1	$5K	Hold	69	–	–	﹤0.01%	2260
2014 Q4	$4K	Sell	69 -30	-30%	-$1.51K	﹤0.01%	2359
2014 Q3	$4K	Hold	99	–	–	﹤0.01%	2291
2014 Q2	$6K	Buy	99 +55	+125%	+$3.2K	﹤0.01%	2142
2014 Q1	$2K	Buy	+44	New	+$2.98K	﹤0.01%	2263

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glenmede Trust's OREX Position: Q2 2016 in Review

Glenmede Trust sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 44 shares.

Glenmede Trust first reported a position in OREX in Q1 2014 and held it in 9 quarters. The position peaked at $6K in Q2 2014. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Glenmede Trust reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Glenmede Trust sold 44 Orexigen Therapeutics, Inc. shares in Q2 2016.
Glenmede Trust first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 9 quarters.
Glenmede Trust's Orexigen Therapeutics, Inc. position peaked at $6K in Q2 2014.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.